Schering-Plough CEO Fred Hassan: An Interview With “The Pink Sheet” DAILY (Part 2 of 3)
This article was originally published in The Pink Sheet Daily
Executive Summary
Hassan discusses changes in the industry, the importance of emerging markets such as Asia, the debate over follow-on biologics and the PDUFA reauthorization.
You may also be interested in...
Schering-Plough’s R&D Spending Surges Ahead Of Sales Gains
The firm’s large number of Phase III products are an expensive opportunity.
Schering-Plough’s R&D Spending Surges Ahead Of Sales Gains
The firm’s large number of Phase III products are an expensive opportunity.
Schering-Plough Licenses Late-Stage Candidate For Use In Coronary Bypass Surgery
Schering intends to continue development of PeriCor’s novel drug “at an accelerated pace,” the company told “The Pink Sheet” DAILY.